Core Viewpoint - The report indicates that the medical device sector is experiencing a narrow fluctuation, with the benchmark index for medical devices declining by 0.98% in the second quarter of 2025. However, there are signs of potential recovery in the third quarter due to high growth rates in bidding data and supportive policies for high-end medical devices [4]. Group 1: Fund Overview - The fund is named "Yongying CSI All-Index Medical Device ETF" and operates as an open-ended index fund, with a total of 3,780,037,843 shares at the end of the reporting period [2]. - The fund aims to closely track the performance of its benchmark index, with a target annual tracking error of less than 2% and an average daily tracking deviation of no more than 0.2% [2][5]. Group 2: Financial Performance - The fund's net asset value per share at the end of the reporting period was 0.4806 RMB, with a net value growth rate of -0.17% during the quarter, compared to a benchmark return of -0.98% [5]. - Over the past three months, the fund's net value growth rate was -0.17%, while the benchmark's was -0.98%. For the past six months, the fund's return was -0.89% against the benchmark's -1.71% [3][5]. Group 3: Investment Strategy - The fund employs a full replication strategy, investing in each stock according to the composition and weight of the benchmark index, and rebalancing the portfolio as necessary [5]. - The fund's investment is primarily in stocks, with 99.67% of total assets allocated to equities, specifically in the manufacturing sector, which accounts for 94.58% of the fund's net asset value [6][7]. Group 4: Market Outlook - The medical device industry is expected to see significant performance improvements in the third quarter, driven by high growth in bidding data and supportive government policies for high-end medical devices [4]. - The integration of AI technologies in medical devices is anticipated to enhance the sector's growth potential, with many companies adopting AI models to accelerate innovation [4].